Jeffrey M Leiden sold $32M of VRTX
Executive Chairman at VERTEX PHARMACEUTICALS INC / MA. 73,292 shares at an average of $440.60, traded Nov 13, 2025, filed Nov 17, 2025.
Score components
- +20RoleChair
- +25Trade size$32.3M at market
- +20Share of holdings soldSold 100% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000875320-25-000234, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 13, 2025 | MOption exercise Common Stock10b5-1 | +19,688 | $91.05 | $1.8M | 43,714 | Nov 17, 2025 |
| Nov 13, 2025 | SOpen-market sale Common Stock10b5-1 | -18,528 | $440.22 | $8.2M | 25,186 | Nov 17, 2025 |
| Nov 13, 2025 | SOpen-market sale Common Stock10b5-1 | -1,160 | $441.05 | $512k | 24,026 | Nov 17, 2025 |
| Nov 14, 2025 | MOption exercise Common Stock10b5-1 | +13,835 | $91.05 | $1.3M | 37,861 | Nov 17, 2025 |
| Nov 14, 2025 | MOption exercise Common Stock10b5-1 | +39,769 | $86.52 | $3.4M | 77,630 | Nov 17, 2025 |
| Nov 14, 2025 | SOpen-market sale Common Stock10b5-1 | -32,234 | $440.30 | $14M | 45,396 | Nov 17, 2025 |
| Nov 14, 2025 | SOpen-market sale Common Stock10b5-1 | -21,330 | $441.35 | $9.4M | 24,066 | Nov 17, 2025 |
| Nov 14, 2025 | SOpen-market sale Common Stock10b5-1 | -40 | $442.00 | $18k | 24,026 | Nov 17, 2025 |
| Nov 13, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -19,688 | $0.00 | $0 | 13,836 | Nov 17, 2025 |
| Nov 14, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -13,835 | $0.00 | $0 | 1 | Nov 17, 2025 |
| Nov 14, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -39,769 | $0.00 | $0 | 63,781 | Nov 17, 2025 |
Related signals
Other insiders at VERTEX PHARMACEUTICALS INC / MA and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 20Weak | VERTEX PHARMACEUTICALS INC / MA | Carmen Bozic EVP and CMO | $1.1M 2,329 shares | -7% | |
| 20Weak | VERTEX PHARMACEUTICALS INC / MA | Carmen Bozic EVP and CMO | $1.1M 2,329 shares | -6% | |
| 35Weak | VERTEX PHARMACEUTICALS INC / MA | Carmen Bozic EVP and CMO | $1.1M 2,329 shares | -6% | |
| 21Weak | VERTEX PHARMACEUTICALS INC / MA | Kristen Ambrose SVP & Chief Accounting Officer | $173k 357 shares | -5% | |
| 20Weak | VERTEX PHARMACEUTICALS INC / MA | Kristen Ambrose SVP & Chief Accounting Officer | $108k 223 shares | -3% | |
| 24Weak | VERTEX PHARMACEUTICALS INC / MA | Edward Morrow Atkinson III EVP, Chief Technical Ops. Off. | $325k 668 shares | -3% | |
| 27Weak | VERTEX PHARMACEUTICALS INC / MA | Jonathan Biller EVP and Chief Legal Officer | $460k 945 shares | -6% | |
| 24Weak | VERTEX PHARMACEUTICALS INC / MA | Mark E. Bunnage EVP, Chief Scientific Officer | $302k 620 shares | -8% | |
| 40Moderate | VERTEX PHARMACEUTICALS INC / MA | Kristen Ambrose SVP & Chief Accounting Officer | $1.1M 2,195 shares | -22% | |
| 40Moderate | VERTEX PHARMACEUTICALS INC / MA | Edward Morrow Atkinson III EVP, Chief Technical Ops. Off. | $1.4M 2,848 shares | -12% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.